Profiel
Dr. Cyrill Zimmermann is a Head of Healthcare Funds & Mandates at Bellevue Asset Management AG.
He is on the Board of Directors at Bellevue Asset Management AG.
Dr. Zimmermann was previously employed as Co-Founder & Chief Executive Officer by Adamant Biomedical Investments AG.
From 1996 to 2000 he worked at the Management Team BB Medtech at Bellevue Asset Management AG.
From 1993 to 1996, he worked as an asset manager for institutional clients at Credit Suisse.
Before this, he was a General Director.
He gained his Ph.D.
from the University of Zurich.
Actieve functies van Cyrill Zimmermann
| Bedrijven | Functie | Begin |
|---|---|---|
Bellevue Asset Management AG
 Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Head-Equity Investments | 01-01-2015 |
Eerdere bekende functies van Cyrill Zimmermann
| Bedrijven | Functie | Einde |
|---|---|---|
Adamant Biomedical Investments AG
 Adamant Biomedical Investments AG Investment ManagersFinance Adamant Biomedical Investments AG (Adamant) is the subsidiary of Bellevue Group AG (SW: BBN) in Switzerland. The firm was established in 2000 as a joint venture between Swiss Life Asset Management and three partners, formerly with the Bellevue Group (which comprises BB Biotech and BB Medtech). The firm's name derives from the Greek word for 'uncut diamond' and refers to their philosophy of uncovering hidden value. Located in Zurich, Adamant is a biomedical sector specialist. The firm manages sector-specific portfolios domiciled in Luxembourg. Their clients are institutions. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Adamant Biomedical Investments AG
Adamant Biomedical Investments AG Investment ManagersFinance Adamant Biomedical Investments AG (Adamant) is the subsidiary of Bellevue Group AG (SW: BBN) in Switzerland. The firm was established in 2000 as a joint venture between Swiss Life Asset Management and three partners, formerly with the Bellevue Group (which comprises BB Biotech and BB Medtech). The firm's name derives from the Greek word for 'uncut diamond' and refers to their philosophy of uncovering hidden value. Located in Zurich, Adamant is a biomedical sector specialist. The firm manages sector-specific portfolios domiciled in Luxembourg. Their clients are institutions. | Finance |
Bellevue Asset Management AG
Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG. | Finance |
